IL-4 up-regulates cyclooxygenase-1 expression in macrophages

J Biol Chem. 2017 Sep 1;292(35):14544-14555. doi: 10.1074/jbc.M117.785014. Epub 2017 Jul 6.

Abstract

Macrophages use various cell-surface receptors to sense their environment and undergo polarized responses. The cytokines, interleukin (IL)-4 and IL-13, released from T-helper type 2 (Th2) cells, drive macrophage polarization toward an alternatively activated phenotype (M2). This phenotype is associated with the expression of potent pro-resolving mediators, such as the prostaglandin (PG) D2-derived cyclopentenone metabolite, 15d-PGJ2, produced by the cyclooxygenase (Ptgs; Cox) pathway. Interestingly, IL-4 treatment of bone marrow-derived macrophages (BMDMs) significantly down-regulates Cox-2 protein expression, whereas Cox-1 levels are significantly increased. This phenomenon not only challenges the dogma that Cox-1 is only developmentally regulated, but also demonstrates a novel mechanism in which IL-4-dependent regulation of Cox-1 involves the activation of the mechanistic target of rapamycin complex (mTORC). Using specific chemical inhibitors, we demonstrate here that IL-4-dependent Cox-1 up-regulation occurs at the post-transcriptional level via the Fes-Akt-mTORC axis. Activation of AMP-activated protein kinase (AMPK) by metformin, inhibition of mTORC by torin 1, or CRISPR/Cas9-mediated genetic knock-out of tuberous sclerosis complex-2 (Tsc2) blocked the IL-4-dependent expression of Cox-1 and the ability of macrophages to polarize to M2. However, use of 15d-PGJ2 partially rescued the effects of AMPK activation, suggesting the importance of Cox-1 in macrophage polarization as also observed in a model of gastrointestinal helminth clearance. In summary, these findings suggest a new paradigm where IL-4-dependent up-regulation of Cox-1 expression may play a key role in tissue homeostasis and wound healing during Th2-mediated immune responses, such as parasitic infections.

Keywords: mTOR complex (mTORC); metformin; parasite; post-transcriptional regulation; prostaglandin.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • AMP-Activated Protein Kinases / chemistry
  • AMP-Activated Protein Kinases / metabolism*
  • Animals
  • Bone Marrow Cells / drug effects
  • Bone Marrow Cells / immunology
  • Bone Marrow Cells / metabolism
  • Bone Marrow Cells / pathology
  • Cells, Cultured
  • Cyclooxygenase 1 / genetics
  • Cyclooxygenase 1 / metabolism
  • Enzyme Activation / drug effects
  • Enzyme Induction / drug effects
  • Enzyme Inhibitors / pharmacology
  • HEK293 Cells
  • Humans
  • Immunomodulation / drug effects
  • Interleukin-4 / genetics
  • Interleukin-4 / metabolism*
  • Ligands
  • Luminescent Proteins / genetics
  • Luminescent Proteins / metabolism
  • Macrophage Activation* / drug effects
  • Macrophages / drug effects
  • Macrophages / immunology
  • Macrophages / metabolism*
  • Macrophages / pathology
  • Male
  • Membrane Proteins / agonists*
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism
  • Metformin / pharmacology
  • Metformin / therapeutic use
  • Mice, Inbred C57BL
  • Models, Immunological*
  • Nippostrongylus / drug effects
  • Nippostrongylus / growth & development
  • Nippostrongylus / immunology
  • Prostaglandin D2 / analogs & derivatives
  • Prostaglandin D2 / metabolism
  • Prostaglandin D2 / therapeutic use
  • Recombinant Proteins / metabolism
  • Strongylida Infections / immunology
  • Strongylida Infections / metabolism
  • Strongylida Infections / pathology
  • Strongylida Infections / prevention & control

Substances

  • 15-deoxyprostaglandin J2
  • Enzyme Inhibitors
  • Ligands
  • Luminescent Proteins
  • Membrane Proteins
  • Recombinant Proteins
  • Interleukin-4
  • Metformin
  • Cyclooxygenase 1
  • Ptgs1 protein, mouse
  • AMPK alpha1 subunit, mouse
  • AMP-Activated Protein Kinases
  • Prostaglandin D2